Join Growin Stock Community!

Black diamond therapeutics, inc.BDTX.US Overview

US StockHealthcare
(No presentation for BDTX)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

BDTX AI Insights

BDTX Overall Performance

BDTX AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

BDTX Recent Performance

-3.04%

Black diamond therapeutics, inc.

0.05%

Avg of Sector

-0.31%

S&P500

BDTX PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

BDTX Key Information

BDTX Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

BDTX Profile

Black Diamond Therapeutics, Inc., a biotechnology company, discover, develops, and commercializes medicines for patient with genetically defined tumors. It develops BDTX-189, an irreversible small molecule inhibitor that is designed to targets oncogenic proteins defined by the non-canonical epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 driver mutations. The company is also developing BDTX-1535, a brain-penetrant inhibitor of EGFR mutations, including canonical, intrinsic resistance, and acquired resistance mutations; and BDTX-4933, a brain-penetrant inhibitor of oncogenic BRAF class I, II and III alterations. It has a strategic partnership with OpenEye Scientific Software, Inc. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

Price of BDTX

BDTX FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

BDTX Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
0.38
PE Ratio (TTM)
6.68
Forward PE
-
PS Ratio (TTM)
2.01
PB Ratio
1.12
Price-to-FCF
6.38
METRIC
VALUE
vs. INDUSTRY
Gross Margin
100.00%
Net Margin
30.71%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
0.38
PE Ratio (TTM)
6.68
Forward PE
-
PS Ratio (TTM)
2.01
PB Ratio
1.12
Price-to-FCF
6.38
Gross Margin
100.00%
Net Margin
30.71%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%

  • When is BDTX's latest earnings report released?

    The most recent financial report for Black diamond therapeutics, inc. (BDTX) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating BDTX's short-term business performance and financial health. For the latest updates on BDTX's earnings releases, visit this page regularly.

  • Where does BDTX fall in the P/E River chart?

    According to historical valuation range analysis, Black diamond therapeutics, inc. (BDTX)'s current price-to-earnings (P/E) ratio is 10.55, placing it in the Undervalued zone on the P/E River chart. This level indicates that the market's expectations for future earnings are already reflected in the share price, with the valuation currently leaning conservative. Investors are advised to further examine the company's fundamentals and its position in the industry cycle to validate whether the valuation is justified.

  • How much cash does BDTX have?

    At the end of the period, Black diamond therapeutics, inc. (BDTX) held Total Cash and Cash Equivalents of 31.69M, accounting for 0.2 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Is BDTX's EPS continuing to grow?

    According to the past four quarterly reports, Black diamond therapeutics, inc. (BDTX)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at -0.15. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of BDTX?

    Black diamond therapeutics, inc. (BDTX)'s Free Cash Flow (FCF) for the period is -7.85M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 30.39% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.

  • What are the PEG ratio and PE ratio of BDTX?

    The latest valuation data shows Black diamond therapeutics, inc. (BDTX) has a Price-To-Earnings (PE) ratio of 10.55 and a Price/Earnings-To-Growth (PEG) ratio of 0.3. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.